Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 80.
THEOCLEAR L.A.-260 vs THEOCLEAR-80
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
Inhibits phosphodiesterase, increasing cAMP levels, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthmaChronic obstructive pulmonary disease (COPD)
Treatment of asthmaManagement of chronic obstructive pulmonary disease (COPD)
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation.
Primarily hepatic via CYP1A2 and to a lesser extent CYP3A4.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 40% bound, primarily to albumin.
Volume of distribution: 0.4-0.5 L/kg, indicating distribution into total body water. Higher Vd in neonates and patients with obesity.
0.3–0.7 L/kg (mean 0.45 L/kg); approximates total body water.
Oral bioavailability: 96% to 100% for immediate-release formulations; sustained-release formulations have similar bioavailability but with prolonged absorption.
Oral: 96–100% (immediate-release); food may affect rate but not extent.
No specific GFR-based dose adjustment recommended; however, monitor serum levels closely in renal impairment (CrCl <30 mL/min) due to potential accumulation of metabolites.
GFR <30 mL/min: reduce dose by 50% and monitor serum levels. GFR 30-50 mL/min: reduce dose by 25%.
Avoid use in Child-Pugh class C; for Child-Pugh class A or B, reduce dose by 50% and monitor serum concentrations.
Child-Pugh Class B or C: reduce dose by 50% and monitor levels; contraindicated in severe hepatic impairment.
Children 6 months-9 years: Starting dose 12-14 mg/kg/day orally divided every 4-6 hours (immediate-release) or every 12 hours (sustained-release). Children 9-16 years: 12-14 mg/kg/day (max 900 mg/day) divided every 6-8 hours (immediate-release) or every 12 hours (sustained-release). Adjust to serum level 5-15 mcg/mL.
Weight-based: 5-10 mg/kg/dose every 6 hours; maximum 300 mg/day for infants <1 year, 600 mg/day for children 1-9 years, 800 mg/day for adolescents.
Elderly patients (≥60 years): Start at 300 mg/day orally (sustained-release) in divided doses every 12 hours; titrate slowly, monitor serum levels, as clearance is reduced.
Start at lowest effective dose; monitor serum levels closely due to reduced clearance; maximum 400 mg/day initially, titrate slowly.
No FDA black box warning.
No FDA black box warning.
Monitor serum theophylline levels to avoid toxicity; use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, or COPD exacerbation; may interact with multiple drugs altering clearance.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with concurrent medications or conditions affecting metabolism.
Hypersensitivity to theophylline or any component; active seizure disorder not controlled by therapy.
Hypersensitivity to theophylline, active seizure disorder, uncontrolled arrhythmias.
Data Pending Review
Data Pending Review
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate theophylline's CNS stimulant effects and toxicity. Concurrent ingestion of charcoal-broiled meats may increase theophylline clearance, potentially reducing efficacy. Grapefruit juice has been reported to increase theophylline levels; limit intake. A high-protein diet may increase clearance; maintain consistent dietary habits.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, chocolate, cola). Charcoal-broiled foods may reduce theophylline absorption. High-protein, low-carbohydrate diets may alter clearance. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with transient neonatal toxemia (e.g., jitteriness, tachycardia, vomiting) if maternal levels are high near term. Risk of respiratory distress syndrome or neonatal apnea is theoretical only.
Theophylline (THEOCLEAR-80) is FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies show increased fetal resorptions and delayed skeletal ossification at high doses. Second and third trimesters: possible increased risk of fetal tachycardia and jitteriness due to placental transfer; neonatal theophylline levels approximate maternal levels. Avoid use unless clearly needed.
Theophylline is excreted into breast milk (M/P ratio approximately 0.6-0.7). Mean milk concentration is about 60-70% of maternal plasma. Relative infant dose is ~10% of maternal weight-adjusted dose. May cause irritability or insomnia in nursing infants, especially at high maternal doses. Benefits likely outweigh risks for asthma therapy, but monitor infant for signs of theophylline toxicity.
Theophylline excreted into breast milk; milk-to-plasma ratio approximately 0.7. Peak milk levels occur 1-2 hours after dose. Reported infant adverse effects include irritability and jitteriness. Weigh risks vs benefits; monitor infant for signs of theophylline toxicity. Avoid if infant has compromised cardiovascular status.
Pregnancy decreases theophylline clearance by 20-40% (especially third trimester). Dose may need reduction by 30-50% to maintain therapeutic levels, with close serum monitoring and adjustment every 2-4 weeks as pregnancy progresses. Smoking cessation (common in pregnancy) further reduces clearance and necessitates dose reduction.
Pregnancy reduces theophylline clearance due to decreased hepatic metabolism and increased volume of distribution, especially in third trimester. Dose adjustments may be required: target serum levels 5-12 mcg/mL. Consider a 20-30% dose reduction in third trimester; monitor levels frequently. Postpartum clearance returns to prepregnancy levels within 2-4 weeks, necessitating dose increase.
Category C
Category C
Theo-24 (theophylline extended-release) has a narrow therapeutic index (5-15 mcg/mL). Monitor serum levels due to significant interindividual variability in clearance. Avoid in patients with active peptic ulcer disease or seizure disorders unless absolutely necessary. Cimetidine, ciprofloxacin, and macrolides increase levels; smoking and rifampin decrease levels. Use with caution in heart failure, hepatic impairment, and elderly due to reduced clearance. For acute exacerbations, consider short-acting beta-agonists first.
Theophylline (THEOCLEAR-80) has a narrow therapeutic index (10-20 mcg/mL). Monitor serum levels closely, especially in patients with hepatic impairment, heart failure, or those on drugs that alter its metabolism (e.g., ciprofloxacin, cimetidine, fluvoxamine). Smoking induces metabolism, requiring higher doses. Do not crush or chew extended-release tablets.
Take exactly as prescribed, do not crush or chew extended-release tablets.Avoid sudden discontinuation; may require tapering.Report symptoms of toxicity: nausea, vomiting, insomnia, jitteriness, palpitations, or seizures.Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.Discuss all medications with your doctor, especially antibiotics and heartburn drugs (cimetidine, ciprofloxacin).Do not smoke; smoking increases metabolism and may require dose adjustments.If you miss a dose, take it as soon as remembered unless close to next dose; do not double up.
Take this medication exactly as prescribed, usually every 12 hours for extended-release forms.Do not crush, chew, or break the tablets; swallow them whole.Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.Notify your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.Do not stop taking this medicine abruptly without consulting your doctor.Keep a consistent schedule and do not change brands or formulations without medical advice.